Although we have not found any studies on the effect of selective Cdc42 inhibitors on obesity, it has been shown that systemic administration of a selective small molecule, the Cdc42 inhibitor CASIN, can significantly reduce inflammatory processes in the body and increase life expectancy [237]. Here, CDC42 is linked to obesity disorder.